Search results for "Ascite"

showing 10 items of 100 documents

A laparoscopic risk-adjusted model to predict major complications after primary debulking surgery in ovarian cancer: A single-institution assessment

2016

Abstract Objective To develop and validate a simple adjusted laparoscopic score to predict major postoperative complications after primary debulking surgery (PDS) in advanced epithelial ovarian cancer (AEOC). Methods From January 2006 to June 2015, preoperative, intraoperative, and post-operative outcome data from patients undergoing staging laparoscopy (S-LPS) before receiving PDS (n=555) were prospectively collected in an electronic database and retrospectively analyzed. Major complications were defined as levels 3 to 5 of MSKCC classification. On the basis of a multivariate regression model, the score was developed using a random two-thirds of the population (n=370) and was validated on …

Adultmedicine.medical_specialtyPost-operative complicationsPopulationLaparoscopy; Ovarian cancer; Post-operative complications; Predictive model; Obstetrics and Gynecology; OncologyRisk AssessmentYoung Adult03 medical and health sciencesGynecologic Surgical ProceduresPostoperative Complications0302 clinical medicineOvarian cancerAscitesHumansMedicineMajor complicationLaparoscopy; Ovarian cancer; Post-operative complications; Predictive modelYoung adultLaparoscopyeducationAgedAged 80 and overOvarian Neoplasmseducation.field_of_studyModels Statistical030219 obstetrics & reproductive medicinemedicine.diagnostic_testbusiness.industryReproducibility of ResultsObstetrics and GynecologyMiddle Agedmedicine.diseaseDebulkingSurgerySettore MED/40 - GINECOLOGIA E OSTETRICIAItalyOncologyPredictive model030220 oncology & carcinogenesisFemaleLaparoscopymedicine.symptombusinessOvarian cancerRisk assessment
researchProduct

Synthesis, characterization of diorganotin(IV) complexes of N-(2-hydroxyarylidene)aminoacetic acid and antitumour screening in vivo in ehrlich ascite…

2001

Some new diorganotin(IV) complexes have been prepared by reacting potassium N-(2-hydroxyarylidene)aminoacetate with R2SnCl2(R = Me,nBu,Ph). The complexes have been characterized by 1H,13C,119Sn NMR, IR and 119mSn Mössbauer spectroscopic techniques in combination with elemental analysis. In the solid state, the complexes possess penta- and hexa-coordinated tin centres. The hexa-coordinated tin complexes were found to dissociate in solution, giving rise to penta-coordinated species as revealed by 119Sn NMR spectroscopy. Antitumour screening in vivo of the complexes L4snPh2,L4SnPh2· Ph3SnCl and L4SntBU2·t Bu2SnCl2 (L4 = N-(2-hydroxyacetophenone)aminoacetate) is also reported. Copyright © 2001 …

AldiminesynthesisStereochemistryMossbauer spectroscopyInfrared spectroscopyAntitumour activityanimal cellantineoplastic activitydissociationChemical synthesisMedicinal chemistryEhrlich ascites tumor cellEhrlich ascites carcinomaInorganic Chemistryin vivo studychemistry.chemical_compoundAcetic acidOrganotinmalecomplex formationorganotin compoundcontrolled studyCarboxylateinfrared spectroscopyEhrlich ascites carcinoma cellmouseglycine derivativenuclear magnetic resonance spectroscopychemistry.chemical_classificationSchiff basenonhumananimal modelarticleGeneral ChemistryNuclear magnetic resonance spectroscopysolid stateNMRAmino acidchemistryreaction analysiSettore CHIM/03 - Chimica Generale E InorganicaIRSchiff baseschemical analysi
researchProduct

Portal vein thrombosis and Budd-Chiari syndrome as onset of polycythemia vera

2013

Budd-Chiari syndrome may be defined as a heterogeneous group of vascular disorders characterized by obstruction of hepatic venous return to the level of hepatic venules, supra-hepatic veins, inferior vena cava or right atrium. The main cause of this syndrome is represented by myeloproliferative diseases and, in particular, by polycythemia vera. The latter may cause multiple splanchnic thrombosis, including portal vein thrombosis, particularly important for its clinical outcomes (ascites, collateral vessels genesis, etc.). We report 2 cases of a Budd-Chiari syndrome induced by polycythemia vera characterized by an abnormal clinical onset, both as regards subjects’ age (29 and 39 years old, r…

Budd-Chiari syndromemedicine.medical_specialtySettore MED/09 - Medicina Internalcsh:MedicineInferior vena cavaPolycythemia verapolycythemia verahemic and lymphatic diseasesAscitesmedicinePortal vein thrombosibusiness.industrylcsh:RGeneral Medicinemedicine.diseaseThrombosisSurgeryPortal vein thrombosisBudd-Chiari syndrome portal vein thrombosis myeloproliferative disease polycythemia vera.medicine.veinPortal vein thrombosis; Budd-Chiari syndrome; polycythemia vera;Budd–Chiari syndromemedicine.symptomSplanchnicbusinessVenous return curve
researchProduct

OX40 expression in tumor-associated Tregs as a potential prognostic biomarker and immunotherapeutic target in ovarian cancer.

2015

e16576 Background: Treatment of ovarian cancer (OC) remains very challenging, with 80-85% of the cases still dying after relapse to standard chemotherapy, and novel treatments are urgently needed. Expansion of regulatory T cells (Tregs) is considered the major factor limiting immune responses to OC. Agonist antibodies against the co-stimulatory receptor OX40 have recently demonstrated to abrogate Treg functions and are under clinical evaluation. We thus studied whether OX40 constituted a valid target of OC-associated Tregs. Methods: Treg immunophenotypic analyses were performed by flow cytometry in ascites and OC specimens and studied in association with patients’ outcome Results: CD4+CD25+…

Cancer ResearchChemotherapybusiness.industrymedicine.medical_treatmentFOXP3hemic and immune systemschemical and pharmacologic phenomenaOvarymedicine.diseaseSerous fluidmedicine.anatomical_structureImmune systemOncologyAscitesmedicineCancer researchIL-2 receptormedicine.symptomOvarian cancerbusinessJournal of Clinical Oncology
researchProduct

Catumaxomab with and without prednisolone in patients with malignant ascites due to epithelial cancer: Results from the phase IIIb CASIMAS study

2012

e13097^ Background: The primary objective of this study was to compare catumaxomab with prednisolone (CP) to catumaxomab without prednisolone (C) as 3-hour intraperitoneal (i.p.) infusion by demonstrating superiority for safety and non-inferiority for efficacy of the CP arm. Methods: 219 patients were randomized to catumaxomab plus premedication of 25 mg prednisolone (111 pts) or to catumaxomab alone (108 pts). The primary endpoint was the composite safety score (CSS) summarizing the worst CTCAE grades for the main TEAEs (pyrexia, nausea, vomiting, and abdominal pain). A potential impact of prednisolone on efficacy was assessed by the co-primary endpoint puncture-free survival (PuFS). Furt…

Cancer Researchmedicine.medical_specialtybusiness.industryCatumaxomabEpithelial cancerGastroenterologySurgeryOncologyInternal medicineAscitesPrednisolonemedicineIn patientmedicine.symptombusinessmedicine.drug
researchProduct

Binucleate cells in the Ehrlich ascites tumor. Action of 5-fluorouracil.

1987

Time-dependent frequency distribution of binucleate cells (BC) was studied in Ehrlich ascites tumor (EAT) growing in mice. In animals that received no further treatment, the number of BC increased slowly from 2.6% to 16.5% of total cells within 8 days. In animals that were treated with different doses of 5-fluorouracil (FU) we found clearly higher numbers of BC. The number of BC increased with tumor age. The increase observed after treatment was reached more quickly in animals that had received the highest FU dose. The final number of BC was also dependent on the age of the tumor at the time of FU injection.

Cell NucleusDose-Response Relationship DrugCell BiologyGeneral MedicineBiologyPharmacologyEhrlich ascitesMiceFluorouracilImmunologymedicineMitotic IndexDistribution (pharmacology)AnimalsFemaleFluorouracilCarcinoma Ehrlich TumorAfter treatmentmedicine.drugBiology of the cell
researchProduct

Binucleate cells in the Ehrlich ascites tumor. Autoradiographic labeling

1989

Abstract An autoradiographic study was performed on binucleate and mitotic cells in the Ehrlich ascites tumor (EAT) untreated and after treatment with 5-fluorouracil (FU). The number of binucleate cells was greater in the treated tumor than in the controls. It was also observed that the number of labeled mitoses was greater in the Fu-treated tumor. Autoradiographic labeling showed that the cells that proved to be binucleate had previously passed through S-phase; thus, these cells belonged to the proliferative compartment.

Cell NucleusPathologymedicine.medical_specialtyBinucleated cellsMice Inbred StrainsCell BiologyGeneral MedicineCompartment (chemistry)BiologyTritiumEhrlich ascitesMiceBiochemistryMitotic IndexmedicineAnimalsAutoradiographyFemaleFluorouracilCarcinoma Ehrlich TumorMitosisAfter treatmentThymidineBiology of the Cell
researchProduct

Tertiary cytoreduction in the setting of recurrent ovarian cancer (Review)

2013

Ovarian cancer is the most lethal gynecological malignancy, with aggressive surgical debulking and adjuvant chemotherapy as the main treatment modalities. Optimal debulking during the primary surgery is significantly correlated with prolonged survival. As surgical techniques and chemotherapeutic agents improve, more patients with prolonged survival may face secondary and tertiary recurrences. The role of surgical debulking in secondary cytoreduction (SC) is not clearly defined and is based on retrospective series. The treatment of patients with primary or secondary recurrences generally consists of second-line chemotherapy, but may be performed on medically fit patients in certain circumsta…

Chemotherapymedicine.medical_specialtyCancer Researchbusiness.industrymedicine.medical_treatmentOptimal DebulkingCancerArticlesTertiary cytoreductionDebulkingmedicine.diseaseSettore MED/40 - Ginecologia E OstetriciaSurgeryOncologyAscitesmedicineStage (cooking)medicine.symptomRecurrent ovarian cancerOvarian cancerComplicationbusinessTumoral debulking
researchProduct

The Impact of Antiviral Therapy and the Influence of Metabolic Cofactors on the Outcome of Chronic HCV Infection

2010

Natural history of HCV related chronic hepatitis is influenced and modified by many factors: virus features, coinfections and host characteristics. In particular, a peculiar genetic background of the host by conditioning the occurrence of intracellular metabolic derangements (i.e., insulin resistance) might contribute to accelerate the rate of progression to cirrhosis and eventually the occurrence of hepatocellular carcinoma (HCC) and death. Likely, direct interplays between virus genotype and host genetic background might be hypothesized at this level. Morbidity and mortality in cirrhosis is primarily associated with complications of liver cirrhosis (ascites, hepatic encephalopathy, jaundi…

CirrhosisHepatologybusiness.industryReview ArticleJaundicemedicine.diseaseVirusdigestive system diseasesHCV therapy natural historyInsulin resistanceInterferonHepatocellular carcinomaImmunologyAscitesmedicinelcsh:Diseases of the digestive system. Gastroenterologymedicine.symptomlcsh:RC799-869businessHepatic encephalopathymedicine.drugInternational Journal of Hepatology
researchProduct

Neuraminidase deficiency presenting as non-immune hydrops fetalis

1984

A newborn infant with oedema, ascites and hepatosplenomegaly is described. In ascites fluid foamy macrophages were found, in a liver biopsy cytoplasmic inclusions and membrane-bound vacuoles were seen. Furthermore the child excreted excessive amounts of sialic acid-rich oligosaccharides in the urine, and therefore a neurovisceral degenerative disorder was assumed. The diagnosis of sialidosis was confirmed by enzymatic assay in cultured fibroblasts, in which a complete deficiency of the lysosomal enzyme neuraminidase could be demonstrated. After recurrent septicaemias the child became dystrophic and died at the age of 6 months. Our case is compared with sialidosis observed by other authors, …

Cytoplasmic inclusionHepatosplenomegalyNeuraminidaseOligosaccharidesMucolipidosesalpha-MannosidaseHydrops fetalisMannosidasesAscitesLeukocytesmedicineLysosomal storage diseaseEdemaHumansSialidosisalpha-L-Fucosidasemedicine.diagnostic_testbiologybusiness.industryInfant NewbornFibroblastsbeta-Galactosidasemedicine.diseasebeta-N-AcetylhexosaminidasesHexosaminidasesLiverLiver biopsyPediatrics Perinatology and Child HealthImmunologybiology.proteinFemalemedicine.symptomLysosomesbusinessNeuraminidaseEuropean Journal of Pediatrics
researchProduct